Clinical trials: sponsored by Tongji Hospital
Ovarian Clear Cell Carcinoma
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicate that both bevacizumab and PD-1 inhibitor have clinical benefits for OCCC patients.
- Trial name
- INOVA (NCT04735861)
- Testing
- Sintilimab, Bevacizumab Biosimilar IBI305
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Tongji Hospital
Ovarian Clear Cell Carcinoma
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
The goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ICI)-based therapy in patients with relapsed/refractory ovarian clear…
- Trial name
- NCT06279104
- Testing
- physician's choice of chemotherapy, immune checkpoint inhibitor based therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tongji Hospital
Bowel Preparation
Comparison of Split-dose and Single-dose Bowel Preparation Regimens Using Polyethylene Glycol Electrolyte(PEG)
The goal of this quasi-experimental study was to compare the effect of single-dose and split-dose 3L compound polyethylene glycol electrolyte powder (PEG) regimen on the quality, comfort and tolerability of bowel preparation in…
- Trial name
- PEG (NCT06551883)
- Testing
- different bowel preparation regime, traditional bowel preparation regime
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Tongji Hospital
Ultrasound-guided Regional Anesthesia
Artificial Intelligence Empowered Anesthesia Ultrasound Guided Regional Anesthesia Training
Evaluate the effectiveness of AI powered anesthesia ultrasound in ultrasound-guided regional anesthesia (UGRA) training.
- Trial name
- NCT06546904
- Testing
- Artificial intelligence empowers anesthesia with ultrasound assistance
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Hepatitis B, Chronic
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B
This is a prospective, multicentre observational study of Chronic Hepatitis B （CHB）in different clinical stages. We intend to compare the immune status of various types of CHB patients, and we propose to establish a staging and…
- Trial name
- NCT06525909
- Where
- 5 sites in China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
B Cell Malignancies
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.
This study is a single-center,open-label,single-dose clinical trial of anti-CD20/CD30-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after lymphocyte depletion pre-treatment.
- Trial name
- NCT06519344
- Testing
- anti-CD20/CD30-CAR-T Cells
- Volunteers
- 12 people
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497387
- Testing
- PRG-1801
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Unresectable Hepatocellular Carcinoma
Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy
The goal of this clinical trial is to learn if donafenib combined with or without immunotherapy and local therapy works to treat unresectable hepatocellular carcinoma that has failed in previous therapy.
- Trial name
- NCT06496815
- Testing
- Donafenib, transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy, PD-1,PD-L1
- Volunteers
- 32 people
- Sponsor
- Tongji Hospital
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497361
- Testing
- PRG-2311
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Ultrasound, Thyroid
Clinical Trial to Evaluate the Effectiveness and Safety of a Remote Automated Ultrasound Diagnostic System for Automated Ultrasound Examinations: a Prospective, Multicenter Study
The purpose of this clinical trial is to verify the safety and effectiveness of the remote automatic ultrasound diagnosis system produced by Wuhan Cooper Technology Co., Ltd. for automatic ultrasound examination.
- Conditions
- Ultrasound, Thyroid, Carotid Artery, Liver
- Trial name
- NCT06487312
- Testing
- Test equipment: Name: Remote automatic ultrasound diagnostic system (Wuhan Cooper Technology Co., Ltd.) Model: CORUS-A30
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Ovarian Cancer, Biomarker
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers…
- Trial name
- NCT06483425
- Testing
- Sequencing of DNA, RNA, and Proteins
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
This is a single-center prospective cohort study of predictive factors related to prognosis of ischemic stroke due to large-artery atherosclerosis.
- Trial name
- NCT04847752
- Testing
- carotid artery stenting, carotid endarterectomy, Aspirin
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tongji Hospital
Refractory Thrombocytopenia, Connective Tissue Diseases
Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease
Immune thrombocytopenia (ITP) is a haemorrhagic disorder often associated with CTD. Corticosteroids are the first-line treatment for CTD-associated thrombocytopenia, but not all patients respond well.
- Trial name
- NCT06458803
- Testing
- Eltrombopag
- Volunteers
- 52 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma Non-resectable
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or…
- Trial name
- CCGLC-008 (NCT05717738)
- Testing
- TACE, Lenvatinib, Anti-PD-1 monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Safety and Efficacy, Scalp Nerve Block
Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block
1. Efficacy of a modified auriculotemporal nerve blockade for patients undergoing supratentorial craniotomy 2. Safety of a modified auriculotemporal nerve blockade for patients undergoing supratentorial craniotomy
- Trial name
- NCT05556889
- Testing
- a modified auriculotemporal nerve blockade, Traditional auriculotemporal nerve blockade
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Tongji Hospital
B Cell Lymphoma
A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
This is a single-center, non-randomized clinical study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received CD19 CAR-T therapy.
- Trial name
- NCT04036019
- Testing
- CD20-directed CAR-T cells with CliniMACS Prodigy® system
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
Urinary System Tumor
A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors
This is an open label, dual cohort ,phase II study to explore efficacy and safety of cadonilimab(PD-1/CTLA-4 Bispecific Antibody) combined with standard regimen neoadjuvant treatment in urothelial carcinoma（UC） and renal cell…
- Trial name
- NCT06427057
- Testing
- Cadonilimab plus chemotherapy, Cadonilimab plus TKI
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
Amobarbital Sodium, Hemodynamics Instability
Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions
At present, there are limited data on perioperative efficacy of barbiturates at home and abroad. The purpose of this clinical trial is to observe the effects of amobarbital sodium combined with low-dose propofol on hemodynamics…
- Trial name
- NCT06385756
- Testing
- Amobarbital, Propofol
- Volunteers
- 96 people
- Sponsor
- Tongji Hospital
Anesthesia, Transapical Beating-heart Septal Myectomy
Anesthetic Management for TA-BSM in HOCM
To retrospectively analyze the preoperative, intraoperative and postoperative anesthesia management of patients with hypertrophic cardiomyopathy undergoing TA-BSM in the investigators' hospital, and to provide clinical basis for…
- Conditions
- Anesthesia, Transapical Beating-heart Septal Myectomy, Hypertrophic Cardiomyopathy
- Trial name
- NCT06397092
- Testing
- transapical beating-heart septal myectomy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) for patients with hepatocellular carcinoma and microvascular invasion (MVI) after hepatectomy.
- Trial name
- NCT06089369
- Testing
- Sintilimab (9 cycles), Sintilimab (18 cycles), Active surveillance
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Tongji Hospital